Correction to Lancet Oncol 2012; 13: 549, 554

James ND, Sydes MR, Mason MD, et al, for the STAMPEDE investigators. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012; 13: 549–58—In the summary of this Article, the second sentence of the Findings section should read: “At the preplanned analysis of the second intermediate activity stage, with 305 FFS events (209 in arm A, 96 in arm D), there was no evidence of an advantage for hormone therapy plus celecoxib over hormone therapy alone: HR 0·94 (95% CI 0·74–1·20)”. The first sentence of the fifth paragraph of the Results should read “At this second intermediate analysis, celecoxib showed insufficient evidence of activity, in terms of FFS, for continuation of accrual to this comparison: HR 0·94 from adjusted Cox model (75% CI upper limit 1·03; 95% CI 0·74—1·20; figure 3).” These corrections have been made as of Nov 23, 2012.